Lupin Ltd.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, reflecting heightened market participation and potential directional bets. The stock’s latest open interest rose by 17.74% to 56,371 contracts, up from 47,878 previously, signalling increased investor interest amid a backdrop of mixed price action and sectoral trends.

Lupin Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, reflecting a shift in market positioning and investor sentiment. The 17.9% increase in OI alongside rising volumes suggests heightened speculative activity and potential directional bets on the stock’s near-term trajectory.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent 5.56% decline in its share price to ₹2,245.65 on 12 May 2026, the stock’s longer-term technical indicators and fundamental mojo score suggest a cautiously optimistic outlook for investors.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant 19.5% surge in open interest in its derivatives segment, signalling heightened market activity despite the stock’s recent price underperformance. This development reflects evolving market positioning and potential directional bets amid a backdrop of mixed technical signals and rising investor participation.

Lupin Ltd., a mid-cap pharmaceutical heavyweight, experienced a notable 17.3% increase in open interest in its derivatives segment, signalling heightened market activity despite the stock’s recent price underperformance. This surge in open interest, coupled with volume patterns and shifting investor positioning, offers critical insights into potential directional bets and market sentiment for the stock.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a notable 16.2% increase in open interest (OI) in its derivatives segment on 11 May 2026, signalling heightened market activity despite the stock’s recent price underperformance. This surge in OI, coupled with volume patterns and shifting investor positioning, offers critical insights into potential directional bets and market sentiment surrounding the stock.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a recent price decline, the stock’s derivatives market shows signs of increased speculative interest, raising questions about potential directional bets and future price movements.

Lupin Ltd., a mid-cap pharmaceutical heavyweight, has witnessed a notable surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a recent price decline, the stock’s derivatives market reveals complex directional bets that merit close attention from traders and investors alike.

Lupin Ltd. experienced a notable intraday decline on 11 Jun 2026, touching a low of Rs 2,255, reflecting a 5.17% drop as the stock faced significant price pressure amid broader market weakness and sector underperformance.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters improve notably, shifting from very attractive to attractive. This re-rating, coupled with robust financial metrics and a strong market performance relative to benchmarks, underscores Lupin’s growing appeal for investors seeking quality mid-cap exposure in the pharma space.

Lupin Ltd., one of India's leading transnational pharmaceutical companies, delivered a spectacular fourth-quarter performance for FY26, reporting consolidated net profit of ₹1,460.34 crores—an impressive 89.04% surge year-on-year (YoY) and a robust 24.23% quarter-on-quarter (QoQ) increase. With a market capitalisation of ₹1,10,873 crores, the Mumbai-based pharma major demonstrated strong operational momentum across its global portfolio, marking a decisive turnaround from the subdued performance witnessed in the previous fiscal year.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has demonstrated a marked improvement in its financial performance for the quarter ended March 2026. The company’s latest results reveal record-breaking revenue and profit figures, prompting an upgrade in its investment rating to Strong Buy with a Mojo Score of 87.0. This article analyses Lupin’s recent quarterly performance in the context of its historical trends and broader market returns.

Rs 2,400 put options on Lupin Ltd. attracted 2,337 contracts on 8 May 2026, representing significant activity just below the current stock price of Rs 2,417. This surge in put trading, combined with the stock’s recent price action and technical positioning, suggests a nuanced picture of hedging rather than outright bearish conviction.

6,333 call contracts on Lupin Ltd. changed hands on 08 May 2026, with the stock closing at Rs 2,414.30, just 2.97% shy of the Rs 2,500 strike price. This close proximity between the underlying price and the strike suggests a focused directional bet in the options market, aligning closely with the cash market's recent price action.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, witnessed significant trading activity on 8 May 2026, with a total traded value exceeding ₹216 crore. Despite a modest decline of 1.62% in its share price, the stock remains a focal point for institutional investors, buoyed by a recent upgrade to a Strong Buy rating and sustained momentum above key moving averages.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 12.57% increase in open interest (OI) in its derivatives segment, signalling heightened market activity and evolving investor positioning. Despite a modest decline in its share price, the surge in OI alongside robust volume patterns suggests a complex interplay of directional bets and market sentiment.

With a decisive break above Rs 2484.5, Lupin Ltd. has reached a fresh 52-week high, extending its upward momentum amid a backdrop of strong technical signals and improving fundamentals.